Articles Archives - Page 366 of 756

TuesdayNov 23, 2021 8:00 am

Friendable Inc. (FDBL) CEO Robert A. Rositano Jr. Discusses Fan Pass Platform Past, Present, and Future with The Hype Magazine

Rositano Jr. is looking for the Fan Pass Live artist platform to expand its global reach and become a household name in the near future The live interview put Fan Pass into the spotlight and introduced the platform to Hype’s estimated audience of 300,000 readers and its social media following of over 484k on Instagram and over 189k on Twitter Rositano Jr. made it clear during the interview that great things are planned from Friendable for the Fan Pass platform in the new year Music has always found a place in the lives of Robert A. Rositano Jr. and his…

TuesdayNov 23, 2021 8:00 am

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Launches Global Bitcoin Lightning Network Platform

LQwD’s proprietary, multi-pronged Lightning Network platform provides easier access to a decentralized network and payment solution The platform makes it possible for users to create and manage Lightning Network nodes easily; make transactions securely, privately, and almost instantaneous; create channels on the Network with effective routing; request and manage liquidity more efficiently Bitcoin experts have predicted that the price of the cryptocurrency will continue to climb through 2021, potentially hitting highs around USD$80,000 before surging to USD$250,000 by 2025 and a goal of USD$5 million per Bitcoin by 2030 The Lightning Network is a second-layer protocol sitting above the Bitcoin…

MondayNov 22, 2021 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland

Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in Miami He shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experience Dr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for smoking cessation, set to commence in early 2022, building on the success of this recent study Mydecine is also set to support Dr. Johnson’s concurrent NIDA grant-funded study through the provision of MYCO-001 for research Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), back in September…

MondayNov 22, 2021 8:00 am

COVID-19 Spurred Rapid Growth for iGaming Industry, Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) Positioned Favorably with Privacy-Focused Software

Research and Markets released new online gaming industry report, expecting significant growth with CAGR of 11.94% between 2021-2026 Swedish University study suggests rapid growth in online gaming resulted from COVID-19 lockdowns Grand View Research report predicts online gambling market will reach $127.3 billion by 2027 PLGNF provides multi-tenant gateway that enables online operators to offer popular games that include Live Dealer Casino, E-Table Games, and Daily Fantasy Sports PLGNF's privacy-focused software enables seamless integration at operator level, allows users to access the platform without sharing sensitive data or requiring app store download Research and Markets recently released a report titled…

MondayNov 22, 2021 8:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment

Pharmaceutical company Tryp Therapeutics is investigating the potential of synthetic psychedelic drug candidates to treat unmet medical needs The company is evaluating two drug products labeled TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome and select eating disorders The company has filed its first two INDs with the FDA for planned Ph 2a clinical trials relating to fibromyalgia and eating disorder treatments In the wake of changes recommended by the FDA to the eating disorders trial, Tryp is in the process of updating its protocols and patient consent form to meet the FDA’s expectations Tryp…

FridayNov 19, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

Company releases positive results from preclinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://ibn.fm/0GSuV). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of…

FridayNov 19, 2021 8:00 am

FingerMotion Inc. (FNGR) Poised to Surf Potential Wave of 5G Growth in China Through Partnerships, Mobile Services

U.S.-based mobile tech services provider FingerMotion is laser-focused on the Chinese phone consumer market, building revenues primarily from SMS and MMS services there but expanding into insurance data services with other corporate partners The company’s trademarked big data platform Sapientus handles over half a million transactions daily for its mobile payment and recharge services Analysts have noted the huge potential for upgrade services in China given consumer interest in replacing their high-end smartphones and acquiring 5G network capability Although there were 180 million 5G users at the end of last year, the government has promoted the fast-speed network and among…

FridayNov 19, 2021 8:00 am

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Expands its Product Line with Acquisition of Majority Equity Interests in Eh Coffee Corp. and Portfolio Coffee Inc.

PlantX just acquitted a 53.5% stake at Eh Coffee and a 51% stake at Portfolio Coffee Inc. The acquisition marks PlantX’s addition of coffee to its line of over 5,000 plant-based products PlantX will push products from these two companies on its e-commerce platform and physical XMarket stores PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) just announced the acquisition of a majority equity interest in Eh Coffee Corp. and Portfolio Coffee Inc. for a share consideration of 913,320 PlantX shares and a cash consideration of $434,058.14. This leaves PlantX with a 53.5% and 51% stake at Eh Coffee and…

ThursdayNov 18, 2021 8:00 am

Hero Technologies Inc. (HENC) Subsidiary Looks to Leverage Position in $2B Massachusetts Marijuana Market

HENC subsidiary evaluating, pursuing property acquisitions; beginning process to obtain cultivation, sales licenses Sales have doubled in the past year, according to state’s seed-to-sale tracking system HENC working with top cannabis law firm to spearhead the process With Massachusetts reporting marijuana sales reaching $2 billion since the state approved the adult-use market (https://ibn.fm/S8IvV), savvy cannabis companies operating in the state are looking to leverage opportunity for growth. Earlier this year, Hero Technologies (OTC: HENC), a cannabis company pursuing a vertically integrated model, announced a new subsidiary: MassCannabis LLC. The newly formed company is evaluating and pursuing property acquisitions and beginning the…

ThursdayNov 18, 2021 8:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes

Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery platform Lexaria will also be conducting pharmacokinetic and efficacy modeling studies in animals to evaluate DehydraTECH’s overall efficiency In 2021, Lexaria Bioscience (NASDAQ: LEXX) raised approximately $15 million in funding. The money allowed for active work programs throughout the year while supporting significant advances in…

Site Search

Company Search

Category: Articles

Friendable Inc. (FDBL) CEO Robert A. Rositano Jr. Discusses Fan Pass Platform Past, Present, and Future with The Hype Magazine

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Launches Global Bitcoin Lightning Network Platform

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland

COVID-19 Spurred Rapid Growth for iGaming Industry, Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) Positioned Favorably with Privacy-Focused Software

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

FingerMotion Inc. (FNGR) Poised to Surf Potential Wave of 5G Growth in China Through Partnerships, Mobile Services

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Expands its Product Line with Acquisition of Majority Equity Interests in Eh Coffee Corp. and Portfolio Coffee Inc.

Hero Technologies Inc. (HENC) Subsidiary Looks to Leverage Position in $2B Massachusetts Marijuana Market

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes

Market Basics

Newsletter Publishers

Public Companies